- Molecular NameTriamterene
- SynonymTriamteren
- Weight255.285
- Drugbank_IDDB00384
- ACS_NO396-01-0
- Show 2D model
- LogP (experiment)0.98
- LogP (predicted, AB/LogP v2.0)-1.39
- pka6.2
- LogD (pH=7, predicted)-4.35
- Solubility (experiment)0.999 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-2.17
- LogSw (predicted, AB/LogsW2.0)2.38
- Sw (mg/ml) (predicted, ACD/Labs)1.62
- No.of HBond Donors7
- No.of HBond Acceptors7
- No.of Rotatable Bonds1
- TPSA128.23
- StatusFDA approved
- AdministrationN/A
- PharmacologyA potassium-sparing diuretic used in combination with thiazide diuretics for the treatment of hypertension and edema.
- Absorption_valueN/A
- Absorption (description)Rapidly absorbed, with somewhat less than 50% of the oral dose reaching the urine.
- Caco_2N/A
- Bioavailability51.0
- Protein binding61.0
- Volume of distribution (VD)13.4 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmTriamterene is primarily metabolized to the sulfate conjugate of hydroxytriamterene. Both the plasma and urine levels of this metabolite greatly exceed triamterene levels.
- Half life4.2 h
- Excretionurine/bile/feces
- Urinary Excretion52
- Clerance63 ml/min/kg
- ToxicityIn the event of overdosage it can be theorized that electrolyte imbalance would be the major concern, with particular attention to possible hyperkalemia. Other symptoms that might be seen would be nausea and vomiting, other G.I. disturbances, and weakness. It is conceivable that some hypotension could occur. The oral LD50 in mice is 380 mg/kg.
- LD50 (rat)N/A
- LD50 (mouse)N/A